MorphoSys AG, of Munich, Germany, appointed Jvrg Reinhardt to its supervisory board.

NeoTherapeutics Inc., of Irvine, Calif., said its subsidiary, NeoGene Technologies, named Huda Akil, Floyd Bloom, Sydney Brenner, Richard Houghten, James McGaugh and Olivier Civelli to its scientific advisory board.

NuTec Sciences Inc., of Atlanta, named Harold Ingalls president and CEO.

Ontogen Corp., of Carlsbad, Calif., appointed Jeff Riley vice president, strategy and corporate development.

PowderJect Pharmaceuticals plc, of Oxford, UK, appointed Staph Bakali chief operating officer.

Reliant Pharmaceuticals LLC, of Liberty Corner, N.J., added Gregory Fulton as senior vice president, marketing.

Replicor Inc., of Montreal, added Luc Paquet as vice president, research and development.

Salus Therapeutics Inc., of Salt Lake City, appointed Gary Hooper to its board.

Sangui BioTech International Inc., of Santa Ana, Calif., elected Dora Malek and Joachim Lutz to its board, as well as the board of its subsidiary, Sangui BioTech Inc.

Shimadzu Biotech, the business unit of Shimadzu Corp., of Kyoto, Japan, appointed Rachel Martin applications laboratory manager of its applications facility.

Tripos Inc., of St. Louis, appointed Bruce Frank vice president of sales, the Americas and Asia; promoted Dieter Schmidt-Bdse to vice president of sales, Europe; and promoted Edward Hodgkin to vice president of global business development.

Vertex Pharmaceuticals Inc., of Cambridge, Mass., named Steven Engel vice president, regulatory affairs.

Vivus Inc., of Mountain View, Calif., elected Graham Strachan to its board of directors.